Results 11 to 20 of about 27,196 (258)

Design and Production of Bispecific Antibodies [PDF]

Antibodies, 2019
With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy.
Qiong Wang, Yiqun Chen, Jaeyoung Park, Xiao Liu, Yifeng Hu, Tiexin Wang, Kevin McFarland, Michael J. Betenbaugh   +7 more
doaj   +3 more sources

ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy

OncoImmunology, 2018
The redirection of T cell activity using bispecific antibodies is one of the most promising cancer immunotherapy approaches currently in development, but it is limited by cytokine storm-related toxicities, as well as the pharmacokinetics and tumor ...
Seandean Lykke Harwood, Ana Alvarez-Cienfuegos, Natalia Nuñez-Prado   +2 more
exaly   +2 more sources

Bispecific antibodies for viral immunotherapy [PDF]

Human Vaccines & Immunotherapeutics, 2017
Bispecific antibody engineering, in which binding specificities toward 2 distinct epitopes are combined into a single molecule, can greatly enhance immunotherapeutic properties of monoclonal antibodies.
Elisabeth K. Nyakatura, Alexandra Y. Soare, Jonathan R. Lai   +2 more
doaj   +3 more sources

Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody

Cancer Management and Research, 2023
Darren Pan, Joshua Richter Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USACorrespondence: Darren Pan, One Gustave L.
Darren Pan, Joshua Richter
exaly   +2 more sources

A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity

Life, 2022
B7-H3 plays an important role in tumor apoptosis, proliferation, adhesion, angiogenesis, invasion, migration, and evasion of immune surveillance. It is overexpressed in various human solid tumor tissues.
Yan Feng, Kun Xie, Yanxin Yin, Bingyu Li, Chenyu Pi, Xiaoqing Xu, Tao Huang, Jingming Zhang, Bo Wang, Hua Gu, Jianmin Fang   +10 more
doaj   +1 more source

Bispecific antibody therapies

Hematology, 2023
Abstract Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
de Assis, Luiz Henrique, Fassi, Daniel El, Hutchings, Martin   +2 more
openaire   +3 more sources

Production of native bispecific antibodies in rabbits. [PDF]

PLoS ONE, 2010
BACKGROUND: A natural bispecific antibody, which can be produced by exchanging Fab arms of two IgG4 molecules, was first described in allergic patients receiving therapeutic injections with two distinct allergens.
Wei Wang, Ruihuan Xu, Jinming Li
doaj   +1 more source

Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysis

Fluids and Barriers of the CNS, 2022
Background Treatment with amyloid-β (Aβ) targeting antibodies is a promising approach to remove Aβ brain pathology in Alzheimer's disease (AD) and possibly even slow down or stop progression of the disease.
Ulrika Julku, Mengfei Xiong, Elin Wik, Sahar Roshanbin, Dag Sehlin, Stina Syvänen   +5 more
doaj   +1 more source

Development of brain-penetrable antibody radioligands for in vivo PET imaging of amyloid-β and tau

Frontiers in Nuclear Medicine, 2023
IntroductionAlzheimer's disease (AD) is characterized by the misfolding and aggregation of two major proteins: amyloid-beta (Aβ) and tau. Antibody-based PET radioligands are desirable due to their high specificity and affinity; however, antibody uptake ...
Vinay Banka, Andrew Kelleher, Dag Sehlin, Greta Hultqvist, Einar M. Sigurdsson, Einar M. Sigurdsson, Stina Syvänen, Yu-Shin Ding   +7 more
doaj   +1 more source

Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins

mAbs, 2021
Bispecific antibodies have recently attracted intense interest. CrossMab technology was described in 2011 as novel approach enabling correct antibody light-chain association with their respective heavy chain in bispecific antibodies, together with ...
Marlena Surowka, Wolfgang Schaefer, Christian Klein   +2 more
doaj   +1 more source